The aim of this study was to evaluate the effects of ipriflavone treatment on bone remodeling in primary hyperparathyroidism. Nine patients, 6 females and 3 males (mean +/- SD age 56 +/- 12.5 years) were treated with 1200 mg/day of ipriflavone by oral administration divided in 3 daily doses. All patients were treated for 21 days; in 5 patients treatment was prolonged to 42 days. In all patients the main serum and urinary parameters of bone remodeling were evaluated. The results suggest that ipriflavone affects bone remodeling by inhibiting bone resorption without affecting bone formation. Ipriflavone is, therefore, indicated in the treatment of metabolic bone diseases characterized by a high bone turnover.
EFFECTS OF IPRIFLAVONE ON BONE REMODELING IN PRIMARY HYPERPARATHYROIDISM / Gianfranco, Mazzuoli; Elisabetta, Romagnoli; Vincenzo, Carnevale; Antonella, Scarda; Liliana, Scarnecchia; Maria Teresa, Pacitti; Rossana, Rosso; Minisola, Salvatore. - In: BONE AND MINERAL. - ISSN 0169-6009. - ELETTRONICO. - 19:1(1992), pp. S27-S33. (Intervento presentato al convegno SATELLITE SYMP ON IPRIFLAVONE : A NEW NON-HORMONAL THERAPEUTIC AGENT IN OSTEOPOROSIS, AT THE 11TH INTERNATIONAL CONF ON CALCIUM REGULATING HORMONES tenutosi a FLORENCE, ITALY nel APR 24-29, 1992) [10.1016/0169-6009(92)90863-9].
EFFECTS OF IPRIFLAVONE ON BONE REMODELING IN PRIMARY HYPERPARATHYROIDISM
MINISOLA, Salvatore
1992
Abstract
The aim of this study was to evaluate the effects of ipriflavone treatment on bone remodeling in primary hyperparathyroidism. Nine patients, 6 females and 3 males (mean +/- SD age 56 +/- 12.5 years) were treated with 1200 mg/day of ipriflavone by oral administration divided in 3 daily doses. All patients were treated for 21 days; in 5 patients treatment was prolonged to 42 days. In all patients the main serum and urinary parameters of bone remodeling were evaluated. The results suggest that ipriflavone affects bone remodeling by inhibiting bone resorption without affecting bone formation. Ipriflavone is, therefore, indicated in the treatment of metabolic bone diseases characterized by a high bone turnover.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
